PitchSend

Nuvectis Pharma Investor Presentation Deck

Potent Single Agent Activity in Squamous Cell Cancers Average Tumor Volume (mm³) 700 600 500 400 300 200 100 0 Esophageal Cancer Day 3 Baseline Vehicle Control NXP900 (40 mg/kg) NuvectisPharma, Inc. Day 6 Day 8 Day 10 Day 13 Day 15 Day 17 Day 20 Day 22 Time Day 24 Day 27 KYSE70 cells (YES1 gene amplification is a known genetic alteration) Head and Neck Cancer (tongue) Average Tumor Volume (mm³) 700 600 500 400 300 200 100 0 Vehicle Control Baseline NXP900 (40 mg/kg) Day 3 Day 6 Day 8 Day 10 Day 13 Day 15 Day 17 Day 20 Time Day 22 Day 24 Day 27 Cal27 cells (Heterozygous FAT1 copy loss is a known genetic alteration) 19

View entire presentation